Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.77 |
| ▸ | MARS1 | P56192 | 7/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | BCL2 | P10415 | 3/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | RPA1 | P27694 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17943738 | 0.94 | NR1H2 (0.71) | NR1H2MARS1MDM2MCL1BCL2 | |
| SCHEMBL29496569 | 0.89 | NR1H2 (0.73) | NR1H2MARS1RXRANR1H3PTGS2 | |
| SCHEMBL16566131 | 0.89 | NR1H2 (0.73) | NR1H2MARS1RXRANR1H3PTGS2 | |
| SCHEMBL16566090 | 0.87 | NR1H2 (1.00) | NR1H2RXRANR1H3PTGS2 | |
| SCHEMBL16566124 | 0.87 | NR1H2 (0.70) | NR1H2RXRANR1H3SLC16A3SLC16A1 | |
| SCHEMBL29496560 | 0.87 | NR1H2 (0.70) | NR1H2RXRANR1H3SLC16A3SLC16A1 | |
| SCHEMBL17970790 | 0.86 | NR1H2 (0.72) | NR1H2RXRANR1H3PTGS2 | |
| SCHEMBL16553481 | 0.86 | NR1H2 (0.58) | NR1H2MARS1MDM2MCL1BCL2 | |
| SCHEMBL25878810 | 0.85 | NR1H2 (0.68) | NR1H2RXRANR1H3PTGS2 | |
| SCHEMBL16553546 | 0.84 | NR1H2 (0.67) | NR1H2RXRANR1H3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20220388963-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS INC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220106274-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS, INC. | 2022-04-07 | — | — | US | disclosed |
| US-11034657-B2 | Liver X receptor (LXR) modulators | ELLORA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034657-B2 | Liver X receptor (LXR) modulators | ELLORA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3041835-B1 | LIVER X RECEPTOR (LXR) MODULATORS | ELLORA THERAPEUTICS INC (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3626712-A2 | LIVER X RECEPTOR (LXR) MODULATORS | Ellora Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626712-A2 | LIVER X RECEPTOR (LXR) MODULATORS | Ellora Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20190169131-A1 | LIVER X RECEPTOR (LXR) MODULATORS | RALEXAR THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20160221956-A1 | Liver X Receptor (LXR) Modulators | ALEXAR THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221956-A1 | Liver X Receptor (LXR) Modulators | ALEXAR THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221956-A1 | Liver X Receptor (LXR) Modulators | ALEXAR THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| EP-3041834-A1 | LIVER X RECEPTOR (LXR) MODULATORS | Alexar Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015035027-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035027-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035015-A1 | LIVER X RECEPTOR (LXR) MODULATORS | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | NR1H2, NR1H3, RXRB | NR1H2 1/4885MARS1 3622/4885MDM2 3331/4885 |
| US-20220106274-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885 |
| US-20160221956-A1 | Liver X Receptor (LXR) Modulators | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885 |
| US-20190169131-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885 |
| US-11034657-B2 | Liver X receptor (LXR) modulators | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885 |
| US-20220388963-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885MARS1 2842/4885MDM2 4638/4885 |
| US-20230212127-A1 | LIVER X RECEPTOR (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885MARS1 2719/4885MDM2 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.